Compare Under Armour Inc Class A (UAA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Viatris Inc — how do they compare? Under Armour Inc Class A trades at $7.3 (market cap $3.07B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 6.4× Under Armour Inc Class A's market cap, and Viatris Inc pays a 2.83% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| UAA | VTRS | |
|---|---|---|
Market Cap | $3.07B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.14 | $17.39 |
52-Week Low | $4.17 | $8.74 |
Enterprise Value | $4.70B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UAA) trades at $7.37, down 0.81% today, with mixed signals: technicals are bullish on moving averages but RSI suggests overbought conditions. Fundamentally, the company reported a net loss of $201.27M in 2025 with negative margins, though recent quarters showed earnings beats. Cash flow trends are volatile, with 2025 net cash outflow of $361.87M. News highlights include a new Dodge collaboration and upcoming Q1 2027 earnings on August 7, 2026.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth offers some offset. Analyst consensus is cautious with a $5.96 price target below current levels. Key risks include consumer spending softness and high debt. For investors, stabilization in earnings and cost control are critical for a turnaround, though near-term headwinds persist.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
